Company intelligence / Profile preview
Imbrium Therapeutics
Stamford, Connecticut, United Statesimbriumthera.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Imbrium Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel pharmacologic and biologic therapies for oncology, central nervous system disorders, and non-opioid pain management. Its leading candidates are in Phase 2 clinical trials targeting conditions such as alcohol use disorder and glioblastoma. The company has discontinued or pending programs in neuralgia and anaphylaxis. As a subsidiary of Purdue Pharma L.P., it collaborates with industry and academic partners to advance its pipeline.[1][2][6][7]
- Therapeutic areas
- OncologyImmunologyPsychiatryNeurology
- Modalities
- Small molecules[5]Biologics[5]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborates with commercial and academic partners; specific names not disclosed.[1][2]
Beyond the preview
Go deeper on Imbrium Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imbrium Therapeutics.